|
41 Companies |
|
29 Products |
|
29 Products |
|
22 Mechanisms of Action |
|
2 Trials |
|
854 News |
|
| «12345678910111213...1617» |
- Trial primary completion date, Viral vector: Adjuvanting Viral Vectored Malaria Vaccines With Matrix M (clinicaltrials.gov) - Dec 7, 2014
P1, N=22, Active, not recruiting, Sponsor: University of Oxford
Trial primary completion date: Jun 2014 --> Dec 2014
- Enrollment open: DHART: Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria (clinicaltrials.gov) - Dec 7, 2014
P4, N=216, Recruiting, Sponsor: University of Oxford
Trial primary completion date: Jun 2014 --> Dec 2014 Not yet recruiting --> Recruiting
- || Trial primary completion date: Safer Sex Program for Young African-American Men (clinicaltrials.gov) - Dec 6, 2014
P2, N=620, Recruiting, Sponsor: University of Kentucky
Not yet recruiting --> Recruiting Trial primary completion date: May 2017 --> May 2018
- || Enrollment closed, Trial primary completion date: Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib (clinicaltrials.gov) - Dec 6, 2014
P1, N=56, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire Vaudois
Trial primary completion date: May 2017 --> May 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Jan 2015
- |||| Enrollment open, Enrollment change, Trial primary completion date: Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse (clinicaltrials.gov) - Nov 28, 2014
P2, N=924, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Jan 2015 Active, not recruiting --> Recruiting | N=329 --> 924 | Trial primary completion date: Mar 2013 --> Mar 2015
- Enrollment closed: Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers (clinicaltrials.gov) - Nov 24, 2014
P1, N=39, Active, not recruiting, Sponsor: Infectious Disease Research Institute
Active, not recruiting --> Recruiting | N=329 --> 924 | Trial primary completion date: Mar 2013 --> Mar 2015 Recruiting --> Active, not recruiting
- Enrollment closed: Breast Milk Composition and HIV-exposed/Unexposed Early Infant Growth and Infectious Disease Events (clinicaltrials.gov) - Nov 24, 2014
P=N/A, N=208, Active, not recruiting, Sponsor: Cornell University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: Controlled Human Malaria Infection After Bites From Mosquitoes Infected With Two Novel P. Falciparum Strains (clinicaltrials.gov) - Nov 24, 2014
P=N/A, N=24, Completed, Sponsor: Radboud University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- artemether/lumefantrine / Generic mfg., mefloquine / Generic mfg.
Enrollment closed, Combination therapy: In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy (clinicaltrials.gov) - Nov 19, 2014
P4, N=118, Active, not recruiting, Sponsor: Global Emerging Infections Surveillance and Response System
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- Trial completion, Trial primary completion date: A Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina Faso (clinicaltrials.gov) - Nov 19, 2014
P1/2, N=730, Completed, Sponsor: University of Oxford
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Aug 2014
- | Enrollment open: Trichomonas Vaginalis Repeat Infections Among HIV Negative Women (clinicaltrials.gov) - Nov 18, 2014
P3, N=1664, Recruiting, Sponsor: Tulane University Health Sciences Center
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Aug 2014 Active, not recruiting --> Recruiting
- Trial completion: Congenital Transmission of Lineages I and II of Trypanosoma Cruzi (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=28348, Completed, Sponsor: Tulane University School of Public Health and Tropical Medicine
Active, not recruiting --> Recruiting Recruiting --> Completed
- chloroquine phosphate / Generic mfg.
Enrollment open: CRePViCam: Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia: (clinicaltrials.gov) - Nov 14, 2014
P4, N=100, Recruiting, Sponsor: Institut Pasteur, Cambodia
Recruiting --> Completed Not yet recruiting --> Recruiting
- chloroquine phosphate / Generic mfg., azithromycin / Generic mfg.
Enrollment change, Trial withdrawal: Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis (clinicaltrials.gov) - Nov 13, 2014
P1/2, N=0, Withdrawn, Sponsor: Radboud University
Not yet recruiting --> Recruiting N=25 --> 0 | Not yet recruiting --> Withdrawn
- | cipargamin (KAE609) / Novartis
Enrollment open, Trial initiation date, Trial primary completion date: A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection (clinicaltrials.gov) - Nov 6, 2014
P2, N=48, Recruiting, Sponsor: Novartis Pharmaceuticals
N=25 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting | Initiation date: Aug 2013 --> Jan 2014 | Trial primary completion date: May 2014 --> Jan 2015
- artemether/lumefantrine / Generic mfg.
Enrollment open: Community-based Screening and Treatment of Malaria in Pregnancy: a Cluster-randomized Trial (clinicaltrials.gov) - Nov 5, 2014
P=N/A, N=5400, Recruiting, Sponsor: Royal Tropical Institute
Not yet recruiting --> Recruiting | Initiation date: Aug 2013 --> Jan 2014 | Trial primary completion date: May 2014 --> Jan 2015 Not yet recruiting --> Recruiting
- Trial completion, Trial primary completion date, IO biomarker: A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) (clinicaltrials.gov) - Nov 5, 2014
P4, N=36, Completed, Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Sep 2014
- || trimethoprim/sulfamethoxazole / Generic mfg.
New P3 trial: Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2) (clinicaltrials.gov) - Nov 4, 2014
P3, N=200, Not yet recruiting, Sponsor: University of California, San Francisco
- |||| Eurartesim (dihydroartemisinin/piperaquine) / Medicines for Malaria Venture, Leadiant Biosci
Enrollment open: Eurartesim (clinicaltrials.gov) - Oct 30, 2014
P2, N=100, Recruiting, Sponsor: sigma-tau i.f.r. S.p.A.
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Sep 2014 Not yet recruiting --> Recruiting
- atovaquone/proguanil / Generic mfg.
Enrollment open: BMGF2b: Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=40, Recruiting, Sponsor: Radboud University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment closed: Controlled Human Malaria Infection After Bites From Mosquitoes Infected With Two Novel P. Falciparum Strains (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=24, Active, not recruiting, Sponsor: Radboud University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- chloroquine phosphate / Generic mfg., atovaquone/proguanil / Generic mfg.
Enrollment closed: Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=15, Active, not recruiting, Sponsor: Radboud University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi
Trial completion, Enrollment change, Combination therapy: QuinAct: Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria (clinicaltrials.gov) - Oct 22, 2014
P3, N=2117, Completed, Sponsor: Universiteit Antwerpen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=3600 --> 2117
- Trial termination: Malaria Prevention Cambodia (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=231, Terminated, Sponsor: Armed Forces Research Institute of Medical Sciences, Thailand
Active, not recruiting --> Completed | N=3600 --> 2117 Suspended --> Terminated; Medication safety concern
- primaquine / Generic mfg.
Trial suspension: Antimalarial Drug Resistance With Assessment of Transmission Blocking Activity (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=150, Suspended, Sponsor: David Saunders
Suspended --> Terminated; Medication safety concern Recruiting --> Suspended
- azithromycin / Generic mfg.
Enrollment change, Trial termination: PCL01: Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis (clinicaltrials.gov) - Oct 17, 2014
P2/3, N=48, Terminated, Sponsor: Ana Rabello
Recruiting --> Suspended N=620 --> 48 | Recruiting --> Terminated; Efficacy issues on test arm
- | hydroxyurea / Generic mfg.
Enrollment open, Trial initiation date: NOHARM: Novel Use Of Hydroxyurea in an African Region With Malaria (clinicaltrials.gov) - Oct 17, 2014
P3, N=200, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
N=620 --> 48 | Recruiting --> Terminated; Efficacy issues on test arm Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Sep 2014
- || primaquine / Generic mfg.
New P3 trial, Combination therapy: DAPPI: Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission (clinicaltrials.gov) - Oct 10, 2014
P3, N=120, Recruiting, Sponsor: London School of Hygiene and Tropical Medicine
- | primaquine / Generic mfg., artemether/lumefantrine / Generic mfg.
Enrollment open, Trial initiation date, Combination therapy: Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM) (clinicaltrials.gov) - Oct 10, 2014
P2/3, N=70, Recruiting, Sponsor: London School of Hygiene and Tropical Medicine
Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Sep 2014 Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Oct 2014
- Mosquirix (RTS,S) / GSK
Trial completion: A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S (clinicaltrials.gov) - Oct 2, 2014
P1/2, N=48, Completed, Sponsor: University of Oxford
Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Oct 2014 Active, not recruiting --> Completed
- atovaquone/proguanil / Generic mfg., artemether/lumefantrine / Generic mfg.
Trial completion, Enrollment change: Evaluation of the Riamet (clinicaltrials.gov) - Oct 2, 2014
P4, N=317, Completed, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=640 --> 317
- | Mosquirix (RTS,S) / GSK
New P1/2 trial: A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S (clinicaltrials.gov) - Sep 30, 2014
P1/2, N=60, Active, not recruiting, Sponsor: University of Oxford
- | amphotericin b liposome / Generic mfg.
Enrollment open, Combination therapy, Monotherapy: Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. (clinicaltrials.gov) - Sep 29, 2014
P3, N=132, Recruiting, Sponsor: Drugs for Neglected Diseases
Active, not recruiting --> Completed | N=640 --> 317 Not yet recruiting --> Recruiting
- |||| Lenocta (sodium stibogluconate) / VioQuest
Trial completion: Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome (clinicaltrials.gov) - Sep 29, 2014
P2, N=183, Completed, Sponsor: Drugs for Neglected Diseases
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment closed: Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel (clinicaltrials.gov) - Sep 22, 2014
P1, N=66, Active, not recruiting, Sponsor: Institut National de la Sant
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi, Tivicay (dolutegravir) / ViiV Healthcare
New P1 trial, Combination therapy: DolACT: Dolutegravir Interactions With Artemisinin-based Combination Therapies (clinicaltrials.gov) - Sep 19, 2014
P1, N=46, Not yet recruiting, Sponsor: University of Liverpool
- || Enrollment closed: Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays (clinicaltrials.gov) - Sep 19, 2014
P=N/A, N=2100, Active, not recruiting, Sponsor: Gen-Probe, Incorporated
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | clindamycin phosphate / Generic mfg.
New P1 trial: Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge (clinicaltrials.gov) - Sep 11, 2014
P1, N=45, Recruiting, Sponsor: Sanaria Inc.
- Enrollment open: Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Na (clinicaltrials.gov) - Sep 9, 2014
P1, N=36, Recruiting, Sponsor: U.S. Army Medical Research and Materiel Command
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Trial completion: Evaluation of CL Detect (clinicaltrials.gov) - Sep 8, 2014
P=N/A, N=150, Completed, Sponsor: U.S. Army Medical Research and Materiel Command
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Trial completion, Trial primary completion date: CL Detect (clinicaltrials.gov) - Sep 8, 2014
P=N/A, N=150, Completed, Sponsor: U.S. Army Medical Research and Materiel Command
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Mar 2013 --> Aug 2013
- Trial primary completion date: Acute vs. Delayed Iron: Effect on Red Cell Iron Incorporation in Severe Malaria (clinicaltrials.gov) - Sep 5, 2014
P=N/A, N=100, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Recruiting --> Completed | Trial primary completion date: Mar 2013 --> Aug 2013 Trial primary completion date: May 2014 --> Mar 2015
- Trial completion, Enrollment change: MIA: Malaria and the Safety of Iron Supplements and Iron Fortification (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=23, Completed, Sponsor: Columbia University
Trial primary completion date: May 2014 --> Mar 2015 Recruiting --> Completed | N=120 --> 23
- amodiaquine hydrochloride / Generic mfg.
Enrollment change, Trial primary completion date: Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria (clinicaltrials.gov) - Aug 29, 2014
P2, N=70, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=120 --> 23 N=200 --> 70 | Trial primary completion date: Aug 2014 --> Mar 2015
- gentamicin sulfate / Generic mfg.
Trial primary completion date: Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK) (clinicaltrials.gov) - Aug 22, 2014
P2, N=30, Completed, Sponsor: U.S. Army Medical Research and Materiel Command
N=200 --> 70 | Trial primary completion date: Aug 2014 --> Mar 2015 Trial primary completion date: Jul 2011 --> Mar 2011
- | Enrollment closed: Trichomonas Vaginalis Repeat Infections Among HIV Negative Women (clinicaltrials.gov) - Aug 21, 2014
P3, N=1664, Active, not recruiting, Sponsor: Tulane University Health Sciences Center
Trial primary completion date: Jul 2011 --> Mar 2011 Suspended --> Active, not recruiting
- | sevuparin (DF-02) / Modus Therap, Mahidol Oxford Tropical Medicine Research Unit
Enrollment change, Trial termination: Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria (clinicaltrials.gov) - Aug 19, 2014
P1/2, N=53, Terminated, Sponsor: Dilaforette AB
Suspended --> Active, not recruiting N=95 --> 53 | Recruiting --> Terminated
- Enrollment open: Controlled Human Malaria Infection After Bites From Mosquitoes Infected With Two Novel P. Falciparum Strains (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=24, Recruiting, Sponsor: Radboud University
N=95 --> 53 | Recruiting --> Terminated Not yet recruiting --> Recruiting
- |||| Mosquirix (RTS,S) / GSK
Trial completion: Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria (clinicaltrials.gov) - Aug 19, 2014
P1/2, N=104, Completed, Sponsor: U.S. Army Medical Research and Materiel Command
Not yet recruiting --> Recruiting No longer recruiting --> Completed
- |||||||||| New P3 trial: Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria (clinicaltrials.gov) - Aug 15, 2014
P3, N=300, Not yet recruiting, Sponsor: GlaxoSmithKline